Nhl: Mantle Cell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797457
  • Drug Pipelines
  • 214 pages
  • Datamonitor Healthcare
1 of 3
An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016-25.

This report addresses the following questions:

- What will be driving the growth of the MCL market during 2016-25?
- Which markets will experience the biggest growth?
- Which branded therapies will have the largest impact on the MCL market?
- What is the overall market potential for Imbruvica and Revlimid?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: MANTLE CELL LYMPHOMA

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Imbruvica (ibrutinib)
- Revlimid (lenalidomide)
- Rituxan (rituximab)
- Torisel (temsirolimus)
- Velcade (bortezomib)
- Primary Research Methodology

TREATMENT: MANTLE CELL LYMPHOMA

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends: Localized Stage (I/II)
- Prescribing Trends: Bulky Stage (II/III/IV)

EPIDEMIOLOGY: MANTLE CELL LYMPHOMA

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast: NHL Overall
- Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: MANTLE CELL LYMPHOMA

- Executive Summary
- Product Overview
- Product profile: Imbruvica
- Product profile: Revlimid
- Product profile: Rituxan
- Product profile: Torisel
- Product profile: Treanda
- Product profile: Velcade

PIPELINE: MANTLE CELL LYMPHOMA

- Executive Summary
- Clinical Pipeline Overview.
- Product profile (late stage): Darzalex.
- Product profile (late stage): Gazyva
- Product profile (late stage): KTE-C
- Product profile (late stage): Kyprolis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll